Article
Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Oct 2022
Tanaka Haruyoshi, Tamura Koji, Abe Toshiya, Yoshida Takeichi, Macgregor-Das Anne, Dbouk Mohamad, Blackford Amanda L, Borges Michael, Lennon Anne Marie, He Jin, Burkhart Richard, Canto Marcia Irene, Goggins Michael
Abstract excerpt
BACKGROUND AND AIMS: Serum diagnostic markers of early-stage pancreatic ductal adenocarcinoma (PDAC) are needed, especially for stage I disease. As tumors grow and cause pancreatic atrophy, markers derived from pancreatic parenchyma such as serum carboxypeptidase A (CPA) activity lose diagnostic performance. We evaluated, with CA19-9, serum CPA as a marker of early pancreatic cancer. METHODS: Serum CPA activity...
Topics
- Adenocarcinoma
- Atrophy
- Biomarkers, Tumor
- CA-19-9 Antigen
- Carboxypeptidases A
- Carcinoma, Pancreatic Ductal
- Genotype
- Humans
- Pancreatic Neoplasms